ME
23andMe Holding Co.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$0.61
+0.00%Year over year
Reported trailing growth
- Revenue
- -12.2%
- EBITDA
- +75.8%
- EBIT
- +31.5%
- EPS
- +65.4%
- Free cash flow
- -16.8%
- Operating cash flow
- -20.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -11.3%
- EBITDA
- +46.6%
- EBIT
- +25.1%
- Net income
- +57.9%
- EPS
- +60.6%
- Free cash flow
- -1.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2025